Developing Allogeneic Induced Pluripotent Stem Cell Based Therapies to Kill Cancer Cells with Kleanthis Xanthopoulos Shoreline Biosciences

Kleanthis Xanthopoulos is Co-Founder and CEO of Shoreline Biosciences. He talks about the Shoreline cell therapy platform that uses standardized manufacturing of allogeneic induced pluripotent stem cells to create an effective treatment to kill tumor cells with multiple advantages over autologous T-cell therapies. Kleanthis explains, "We are focusing specifically on two different effector cells, Natural Killers and Macrophages, and we derive them from a platform which is induced pluripotent stem cells. This gives us the ability to really engineer the NK cells and Macrophages that we derive from iPSC, so they become allogeneic standardized, meaning they can be introduced to any patient and then are targeted and specific." "Initial clinical results are showing us that iPSC derived NK cells don't appear to have the kind of side effects that you see with T-cells. So we are very, very excited about that. And we are seeing that there's a different dimension in cell therapies that can be served very, very nicely through these allogeneic pluripotent stem cell based therapies." After the interview, Shoreline announced it has raised $140 million in its latest fundraising round. #ShorelineBio #ShoreBiosciences #Oncology #Immunotherapy #NKCells #iPSC #Macrophages #SanDiego Shorelinebio.com Download the transcript here